Compare IOVA & PRLB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IOVA | PRLB |
|---|---|---|
| Founded | 2007 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Metal Fabrications |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.7B |
| IPO Year | 2008 | 2011 |
| Metric | IOVA | PRLB |
|---|---|---|
| Price | $4.08 | $78.94 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 2 |
| Target Price | $9.00 | ★ $53.00 |
| AVG Volume (30 Days) | ★ 12.1M | 175.3K |
| Earning Date | 05-07-2026 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 14.84 | ★ 33.33 |
| EPS | N/A | ★ 0.33 |
| Revenue | N/A | N/A |
| Revenue This Year | $47.74 | $8.56 |
| Revenue Next Year | $40.31 | $6.89 |
| P/E Ratio | ★ N/A | $236.24 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.67 | $37.91 |
| 52 Week High | $5.63 | $78.68 |
| Indicator | IOVA | PRLB |
|---|---|---|
| Relative Strength Index (RSI) | 53.47 | 65.26 |
| Support Level | $2.07 | $47.27 |
| Resistance Level | $4.35 | N/A |
| Average True Range (ATR) | 0.36 | 3.00 |
| MACD | -0.02 | -0.00 |
| Stochastic Oscillator | 40.45 | 94.44 |
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. It operates in one segment, focusing on innovating, developing, and commercializing therapies using its autologous TIL cell therapies for patients with solid tumor cancers. Geographically, the company operates in United States and Rest of the World.
Proto Labs Inc is an on-demand manufacturer of custom parts for prototyping and short-run production. The company offers developers and engineers quick-turn production services to reduce the time to market. The Lab uses injection molding, computer numerical control machining, and 3-D printing, and sheet metal to manufacture custom parts for its clients. The company services clients' needs for prototype solutions, parts for testing procedures, bridge production capabilities during disruptions in manufacturing processes, limited-quantity requests, and end-of-life production support. Geographically, a majority of the company's revenue is derived from the United States and the rest from Europe.